NDC 0002-8031 Glucagon


NDC Product Code 0002-8031

NDC CODE: 0002-8031

Proprietary Name: Glucagon What is the Proprietary Name?
The proprietary name also known as the trade name is the name of the product chosen by the medication labeler for marketing purposes.

Non-Proprietary Name: Glucagon What is the Non-Proprietary Name?
The non-proprietary name is sometimes called the generic name. The generic name usually includes the active ingredient(s) of the product.

Drug Use Information

Drug Use Information
The drug use information is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate. This information is not individual medical advice and does not substitute for the advice of a health care professional. Always ask a health care professional for complete information about this product and your specific health needs.

  • This medication is the same as your body's own glucagon, a natural substance that raises blood sugar by causing the body to release sugar stored in the liver. It is used to treat very low blood sugar (hypoglycemia) that may cause you to need help from others. Make sure a family member or caregiver knows where you keep this medication and how to use it before you need their help.

NDC Code Structure

  • 0002 - Eli Lilly And Company

NDC 0002-8031-01

Package Description: 1 KIT in 1 KIT * 1 mL in 1 VIAL (0002-7529-01) * 1 mL in 1 SYRINGE (0002-7530-01)

Price per Unit: $270.32378 per EA

NDC Product Information

Glucagon with NDC 0002-8031 is a a human prescription drug product labeled by Eli Lilly And Company. The generic name of Glucagon is glucagon. The product's dosage form is kit and is administered via form. The RxNorm Crosswalk for this NDC code indicates a single RxCUI concept is associated to this product: 310497.

Dosage Form: Kit - A packaged collection of related material.

Product Type: Human Prescription Drug What kind of product is this?
Indicates the type of product, such as Human Prescription Drug or Human Over the Counter Drug. This data element matches the “Document Type” field of the Structured Product Listing.

Inactive Ingredient(s)

About the Inactive Ingredient(s)
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product.

  • WATER (UNII: 059QF0KO0R)

Product Labeler Information

What is the Labeler Name?
Name of Company corresponding to the labeler code segment of the Product NDC.

Labeler Name: Eli Lilly And Company
Labeler Code: 0002
FDA Application Number: NDA020928 What is the FDA Application Number?
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.

Marketing Category: NDA - A product marketed under an approved New Drug Application. What is the Marketing Category?
Product types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Start Marketing Date: 03-01-1999 What is the Start Marketing Date?
This is the date that the labeler indicates was the start of its marketing of the drug product.

Listing Expiration Date: 12-31-2023 What is the Listing Expiration Date?
This is the date when the listing record will expire if not updated or certified by the product labeler.

Exclude Flag: N - NO What is the NDC Exclude Flag?
This field indicates whether the product has been removed/excluded from the NDC Directory for failure to respond to FDA"s requests for correction to deficient or non-compliant submissions ("Y"), or because the listing certification is expired ("E"), or because the listing data was inactivated by FDA ("I"). Values = "Y", "N", "E", or "I".

* Please review the disclaimer below.

Information for Patients


Glucagon is pronounced as (gloo' ka gon)

Why is glucagon medication prescribed?
Glucagon is a hormone produced in the pancreas. Glucagon is used to raise very low blood sugar. Glucagon is also used in diagnostic testing of the stomach and other diges...
[Read More]

* Please review the disclaimer below.

Glucagon Product Label Images

Glucagon Product Labeling Information

The product labeling information includes all published material associated to a drug. Product labeling documents include information like generic names, active ingredients, ingredient strength dosage, routes of administration, appearance, usage, warnings, inactive ingredients, etc.

Product Labeling Index


Glucagon for Injection is a polypeptide
hormone identical to human glucagon that increases blood glucose and relaxes
smooth muscle of the gastrointestinal tract. Glucagon is synthesized in a
special non-pathogenic laboratory strain of Escherichia
coli bacteria that has been genetically altered by the addition
of the gene for glucagon.Glucagon is a single-chain
polypeptide that contains 29 amino acid residues and has a molecular weight
of 3483.The empirical formula is C153H225N43O49S.
The primary sequence of glucagon is shown below.Crystalline glucagon is a white to off-white powder. It is
relatively insoluble in water but is soluble at a pH of less than 3 or more
than 9.5.Glucagon is available for use intravenously,
intramuscularly, or subcutaneously in a kit that contains a vial of sterile
glucagon and a syringe of sterile diluent. The vial contains 1 mg of glucagon and 49 mg of lactose. Hydrochloric acid may have been added during
manufacture to adjust the pH of the glucagon. One International Unit of glucagon
is equivalent to 1 mg of glucagon.1 The diluent syringe contains
12 mg/mL of glycerin, Water For Injection, and hydrochloric acid.


Glucagon increases blood glucose concentration and is used in the treatment of severe hypoglycemia. Glucagon acts only on liver glycogen, converting it to glucose.Glucagon administered
through a parenteral route relaxes smooth muscle of the stomach, duodenum,
small bowel, and colon.

For the treatment of severe hypoglycemia:Glucagon is indicated as a treatment for severe hypoglycemia (low blood sugar) which may occur in patients with diabetes mellitus.
Because patients with type 1
diabetes may have less of an increase in blood glucose levels compared with
a stable type 2 patient, supplementary carbohydrate should be given as soon
as possible, especially to a pediatric patient.

For use as a diagnostic aid:Glucagon is indicated as a diagnostic aid in the radiologic examination of the stomach, duodenum, small bowel, and colon when diminished intestinal motility would be advantageous.Glucagon is as effective for this examination as are the anticholinergic drugs. However, as use of glucagon in combination with anticholinergic drugs may result in increased side effects, the use of glucagon in combination with anticholinergic drugs is not recommended.

Glucagon is contraindicated in patients with known
hypersensitivity to it or in patients with known pheochromocytoma.

Glucagon should be administered cautiously to patients
with a history suggestive of insulinoma, pheochromocytoma, or both. In patients
with insulinoma, intravenous administration of glucagon may produce an initial
increase in blood glucose; however, because of glucagon's hyperglycemic
effect the insulinoma may release insulin and cause subsequent hypoglycemia.
A patient developing symptoms of hypoglycemia after a dose of glucagon should
be given glucose orally, intravenously, or by gavage, whichever is most appropriate.

Exogenous glucagon also stimulates the release of
catecholamines. In the presence of pheochromocytoma, glucagon can cause the
tumor to release catecholamines, which may result in a sudden and marked increase
in blood pressure. If a patient develops a sudden increase in blood pressure,
5 to 10 mg of phentolamine mesylate may be administered intravenously in an
attempt to control the blood pressure.

Generalized allergic reactions, including urticaria,
respiratory distress, and hypotension, have been reported in patients who
received glucagon by injection.

Glucagon is effective in treating hypoglycemia
only if sufficient liver glycogen is present. Because glucagon is of little
or no help in states of starvation, adrenal insufficiency, or chronic hypoglycemia,
hypoglycemia in these conditions should be treated with glucose.

Refer patients and family members to the attached
Information for the User for instructions describing the method of preparing
and injecting glucagon. Advise the patient and family members to become familiar
with the technique of preparing glucagon before an emergency arises. Instruct
patients to use 1 mg for adults and 1/2 the adult dose (0.5 mg)
for pediatric patients weighing less than 44 lb (20 kg).

  • Patients and family members should be informed
  • Of the following measures to prevent hypoglycemic reactions due to insulin:Reasonable uniformity from day to day with regard to diet, insulin,
  • And exercise.Careful adjustment of the insulin program so that the type (or types)
  • Of insulin, dose, and time (or times) of administration are suited to the
  • Individual patient.Frequent testing of the blood or urine for glucose so that a change
  • In insulin requirements can be foreseen.Routine carrying of sugar, candy, or other readily absorbable carbohydrate
  • By the patient so that it may be taken at the first warning of an oncoming
  • Reaction.To prevent severe hypoglycemia, patients and
  • Family members should be informed of the symptoms of mild hypoglycemia and
  • How to treat it appropriately.Family members
  • Should be informed to arouse the patient as quickly as possible because prolonged
  • Hypoglycemia may result in damage to the central nervous system. Glucagon
  • Or intravenous glucose should awaken the patient sufficiently so that oral
  • Carbohydrates may be taken.Patients should
  • Be advised to inform their physician when hypoglycemic reactions occur so
  • That the treatment regimen may be adjusted if necessary.

Blood glucose determinations should be obtained
to follow the patient with hypoglycemia until patient is asymptomatic.

Because glucagon is usually given in a single
dose and has a very short half-life, no studies have been done regarding carcinogenesis.
In a series of studies examining effects on the bacterial mutagenesis (Ames)
assay, it was determined that an increase in
colony counts was related to technical difficulties in running this assay
with peptides and was not due to mutagenic activities of the glucagon.

Reproduction studies have been performed in rats
at doses up to 2 mg/kg glucagon administered two times a day (up to 40 times
the human dose based on body surface area, mg/m2) and have revealed
no evidence of impaired fertility.

Reproduction studies have not been performed with recombinant
glucagon. However, studies with animal-sourced glucagon were performed in
rats at doses up to 2 mg/kg glucagon administered two times a day (up to 40 times
the human dose based on body surface area, mg/m2), and have revealed
no evidence of impaired fertility or harm to the fetus due to glucagon. There
are, however, no adequate and well-controlled studies in pregnant women. Because
animal reproduction studies are not always predictive of human response, this
drug should be used during pregnancy only if clearly needed.

It is not known whether this drug is excreted
in human milk. Because many drugs are excreted in human milk, caution should
be exercised when glucagon is administered to a nursing woman. If the drug
is excreted in human milk during its short half-life, it will be hydrolyzed
and absorbed like any other polypeptide. Glucagon is not active when taken
orally because it is destroyed in the gastrointestinal tract before it can
be absorbed.

For the treatment of severe hypoglycemia: The use of glucagon in pediatric patients has been reported to be safe and effective.2-6

For use as a diagnostic aid: Effectiveness has
not been established in pediatric patients.

Clinical studies of glucagon did not include sufficient
numbers of subjects aged 65 and over to determine whether they respond differently
from younger subjects. Other reported clinical experience has not identified
differences in responses between the elderly and younger patients. In general,
dose selection for an elderly patient should be cautious, usually starting
at the low end of the dosing range, reflecting the greater frequency of decreased
hepatic, renal, or cardiac function, and of concomitant disease or other drug

Signs and
Symptoms — If overdosage occurs, nausea, vomiting, gastric hypotonicity,
and diarrhea would be expected without causing consequential toxicity.Intravenous administration of glucagon has been shown to
have positive inotropic and chronotropic effects. A transient increase in
both blood pressure and pulse rate may occur following the administration
of glucagon. Patients taking β-blockers might be expected to have a greater
increase in both pulse and blood pressure, an increase of which will be transient
because of glucagon's short half-life. The increase in blood pressure
and pulse rate may require therapy in patients with pheochromocytoma or coronary
artery disease.When glucagon was given in
large doses to patients with cardiac disease, investigators reported a positive
inotropic effect. These investigators administered glucagon in doses of 0.5 to
16 mg/hour by continuous infusion for periods of 5 to 166 hours. Total doses
ranged from 25 to 996 mg, and a 21-month-old infant received approximately
8.25 mg in 165 hours. Side effects included nausea, vomiting, and decreasing
serum potassium concentration. Serum potassium concentration could be maintained
within normal limits with supplemental potassium.The
intravenous median lethal dose for glucagon in mice and rats is approximately
300 mg/kg and 38.6 mg/kg, respectively.Because
glucagon is a polypeptide, it would be rapidly destroyed in the gastrointestinal
tract if it were to be accidentally ingested.

— To obtain up-to-date information about the treatment of overdose,
a good resource is your certified Regional Poison Control Center. Telephone
numbers of certified poison control centers are listed in the Physicians'
Desk Reference (PDR). In managing overdosage, consider the possibility
of multiple drug overdoses, interaction among drugs, and unusual drug kinetics
in your patient.In view of the extremely short
half-life of glucagon and its prompt destruction and excretion, the treatment
of overdosage is symptomatic, primarily for nausea, vomiting, and possible
hypokalemia.If the patient develops a dramatic
increase in blood pressure, 5 to 10 mg of phentolamine mesylate has been shown
to be effective in lowering blood pressure for the short time that control
would be needed.Forced diuresis, peritoneal dialysis, hemodialysis, or charcoal hemoperfusion have not been established as beneficial for an overdose of glucagon.

  • General Instructions for Use:The diluent is provided for use only in the preparation of glucagon for parenteral injection and for no other use.
  • Glucagon should not be used at concentrations greater than 1 mg/mL.
  • Reconstituted glucagon should be used immediately. Discard any unused portion.Reconstituted glucagon solutions should be used only if they are clear and of a water-like consistency.
  • Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration.

  • Directions for Treatment of Severe Hypoglycemia:Severe hypoglycemia should be treated initially
  • With intravenous glucose, if possible.If parenteral glucose can not be used, dissolve the lyophilized glucagon
  • Using the accompanying diluting solution and use immediately.For adults and for pediatric patients weighing more than 44 lb (20 kg),
  • Give 1 mg by subcutaneous, intramuscular, or intravenous injection.For pediatric patients weighing less than 44 lb (20 kg), give 0.5 mg or a dose equivalent to 20 to 30 mcg/kg.2-6Discard any unused portion.An unconscious patient will usually awaken within 15 minutes following
  • The glucagon injection. If the response is delayed, there is no contraindication
  • To the administration of an additional dose of glucagon; however, in view
  • Of the deleterious effects of cerebral hypoglycemia emergency aid should be
  • Sought so that parenteral glucose can be given.After the patient responds, supplemental carbohydrate should be given
  • To restore liver glycogen and to prevent secondary hypoglycemia.

Directions for Use as a Diagnostic Aid:Dissolve the lyophilized glucagon using the accompanying
diluting solution and use immediately. Discard any
unused portion.The doses
in the following table may be administered for relaxation of the stomach,
duodenum, and small bowel, depending on the onset and duration of effect required
for the examination. Since the stomach is less sensitive to the effect of
glucagon, 0.5 mg intravenous or 2 mg intramuscular are recommended.
* Administration of 2 mg doses produces a higher incidence of nausea and vomiting than do lower doses.
DoseRoute of AdministrationTime of Onset of ActionApproximate Duration of Effect0.25 mg-0.5 mgIntravenous 1 minute9-17 minutes1 mgIntramuscular 8-10 minutes12-27 minutes2 mg*Intravenous 1 minute22-25 minutes2 mg*Intramuscular 4-7 minutes21-32 minutesFor examination of the colon, it is recommended
that a 2 mg dose be administered intramuscularly approximately 10 minutes
prior to the procedure. Colon relaxation and reduction of patient discomfort
may allow the radiologist to perform a more satisfactory examination.

Reconstitution — Vials of glucagon, as well as the diluent for glucagon, may be stored at controlled room temperature 20° to 25°C (68° to 77°F)[see
USP].The USP defines controlled room temperature
by the following: A temperature maintained thermostatically that encompasses
the usual and customary working environment of 20° to 25°C (68° to 77°F);
that results in a mean kinetic temperature calculated to be not more than 25°C;
and that allows for excursions between 15° and 30°C (59° and 86°F) that are
experienced in pharmacies, hospitals, and warehouses.

Reconstitution — Glucagon for Injection should be used immediately. Discard any unused portion.

Literature revised April 2018Marketed by: Lilly USA, LLCIndianapolis, IN 46285, USACopyright © 1999, 2018, Eli Lilly and Company. All rights reserved.GLU-0002-USPI-20180418


Glucagon has been studied following intramuscular,
subcutaneous, and intravenous administration in adult volunteers. Administration
of the intravenous glucagon showed dose proportionality of the pharmacokinetics
between 0.25 and 2.0 mg. Calculations from a 1 mg dose showed a small volume
of distribution (mean, 0.25 L/kg) and a moderate clearance (mean, 13.5 mL/min/kg).
The half-life was short, ranging from 8 to 18 minutes.Maximum plasma concentrations of 7.9 ng/mL were achieved approximately
20 minutes after subcutaneous administration (see Figure 1A). With
intramuscular dosing, maximum plasma concentrations of 6.9 ng/mL were attained
approximately 13 minutes after dosing.Glucagon
is extensively degraded in liver, kidney, and plasma. Urinary excretion of
intact glucagon has not been measured.


In a study of 25 volunteers, a subcutaneous dose
of 1 mg glucagon resulted in a mean peak glucose concentration of 136 mg/dL
30 minutes after injection (see Figure 1B). Similarly, following
intramuscular injection, the mean peak glucose level was 138 mg/dL, which
occurred at 26 minutes after injection. No difference in maximum blood glucose
concentration between animal-sourced and rDNA glucagon was observed after
subcutaneous and intramuscular injection.Figure 1 Mean (±SE) serum glucagon and blood glucose levels after subcutaneous injection of glucagon (1 mg) in 25 normal volunteers

Adverse Reactions

Side effects may include nausea and vomiting. These reactions may also occur with hypoglycemia.
Generalized allergic reactions have been reported (see WARNINGS). In a
three month controlled study of 75 volunteers comparing animal-sourced glucagon
with glucagon manufactured through rDNA technology, no glucagon-specific antibodies
were detected in either treatment group.

How Supplied

Glucagon Emergency Kit for Low Blood Sugar (NDC 0002-8031-01) contains 1 mg glucagon for injection (as a sterile, lyophilized white to off-white powder) in a single-dose vial and 1 mL of diluent for glucagon in a prefilled syringe.


  • Drug Information for the Health
  • Care Professional. 18th ed. Rockville, Maryland: The United States
  • Pharmacopeial Convention, Inc; 1998; I:1512.Gibbs et al: Use of glucagon to terminate insulin reactions in diabetic
  • Children. Nebr Med J 1958;43:56-57.Cornblath M, et al: Studies of carbohydrate metabolism in the newborn:
  • Effect of glucagon on concentration of sugar in capillary blood of newborn
  • Infant. Pediatrics 1958;21:885-892.Carson MJ, Koch R: Clinical studies with glucagon in children. J Pediatr 1955;47:161-170.Shipp JC, et al: Treatment of insulin hypoglycemia in diabetic campers. Diabetes 1964;13:645-648.Aman J, Wranne L: Hypoglycemia in childhood diabetes II: Effect of subcutaneous
  • Or intramuscular injection of different doses of glucagon. Acta
  • Pediatr Scand 1988;77:548-553.

Information For The User

  • GLUCAGON FOR INJECTION BECOME FAMILIAR WITH THE FOLLOWING INSTRUCTIONS BEFORE AN EMERGENCY ARISES. DO NOT USE THIS KIT AFTER DATE STAMPED ON THE VIAL OF GLUCAGON. IF YOU HAVE QUESTIONS CONCERNING THE USE OF THIS PRODUCT, CONSULT A DOCTOR, NURSE OR PHARMACIST.Make sure that your relatives or close friends know that if you become unconscious, medical assistance must always be sought. Glucagon may have been prescribed so that members of your household can give the injection if you become severely hypoglycemic and are unable to take sugar by mouth. If you are unconscious, glucagon can be given while awaiting medical assistance.Show your family members and others where you keep this
  • Kit and how to use it. They need to know how to use it before you need it.
  • They can practice giving a shot by giving you your normal insulin shots. It
  • Is important that they practice. A person who has never given a shot probably
  • Will not be able to do it in an emergency.IMPORTANTAct quickly. Prolonged unconsciousness may be harmful.These simple instructions will help you give glucagon successfully.Turn patient on his/her side to prevent patient from choking.The contents of the syringe are inactive. You must mix the contents
  • Of the syringe with the glucagon in the accompanying bottle before giving
  • Injection. (See DIRECTIONS FOR USE
  • Coma or insulin reaction resulting from severe hypoglycemia (very low blood sugar).
  • Symptoms of severe hypoglycemia include disorientation, unconsciousness, and
  • Seizures or convulsions. Give glucagon if (1) the patient is unconscious (2) the
  • Patient is unable to eat sugar or a sugar-sweetened product (3) the patient
  • Is having a seizure, or (4) repeated administration of sugar or a sugar-sweetened
  • Product such as a regular soft drink or fruit juice does not improve the patient's
  • Condition. Milder cases of hypoglycemia should be treated promptly by eating
  • Sugar or a sugar-sweetened product. (See INFORMATION
  • ON HYPOGLYCEMIA below for more information on the symptoms of hypoglycemia.)
  • Glucagon is not active when taken orally.DIRECTIONS FOR USETO PREPARE GLUCAGON
  • FOR INJECTIONRemove the flip-off seal from the bottle of glucagon. Wipe rubber stopper
  • On bottle with alcohol swab.
  • Remove the needle protector from the syringe, and inject the entire
  • Contents of the syringe into the bottle of glucagon. DO NOT REMOVE THE PLASTIC
  • CLIP FROM THE SYRINGE. Remove syringe from the bottle.
  • Swirl bottle gently until glucagon dissolves completely. GLUCAGON SHOULD
  • TO INJECT GLUCAGONUse Same Technique as for Injecting InsulinUsing the same syringe, hold bottle upside down and, making sure the
  • Needle tip remains in solution, gently withdraw all of the solution (1 mg
  • Mark on syringe) from bottle. The plastic clip on the syringe will prevent
  • The rubber stopper from being pulled out of the syringe; however, if the plastic
  • Plunger rod separates from the rubber stopper, simply reinsert the rod by
  • Turning it clockwise. The usual adult dose is 1 mg. For children
  • Weighing less than 44 lb (20 kg), give 1/2 adult dose (0.5 mg). For children,
  • Withdraw 1/2 of the solution from the bottle (0.5 mg mark on syringe). DISCARD
  • USING THE FOLLOWING DIRECTIONS, INJECT GLUCAGON IMMEDIATELY AFTER MIXING.Cleanse injection site on buttock, arm, or thigh with alcohol swab.Insert the needle into the loose tissue under the cleansed injection
  • Site, and inject all (or 1/2 for children weighing less than 44 lb) of the
  • Glucagon solution. Apply light pressure at
  • The injection site, and withdraw the needle. Press an alcohol swab against
  • The injection site.Turn the patient on his/her side. When an unconscious person awakens,
  • He/she may vomit. Turning the patient on his/her side will prevent him/her
  • The patient a fast-acting source of sugar (such as a regular soft drink or
  • Fruit juice) and a long-acting source of sugar (such as crackers and cheese
  • Or a meat sandwich). If the patient does not awaken within 15 minutes, give
  • Another dose of glucagon and INFORM A DOCTOR OR EMERGENCY SERVICES IMMEDIATELY.Even if the glucagon revives the patient, his/her doctor should be promptly
  • Notified. A doctor should be notified whenever severe hypoglycemic reactions
  • ON HYPOGLYCEMIAEarly symptoms
  • Of hypoglycemia (low blood glucose) include: sweating drowsiness dizziness sleep disturbances palpitation anxiety tremor blurred vision hunger slurred speech restlessness depressed mood tingling in the hands, feet, lips, or tongue irritability lightheadedness abnormal behavior inability to concentrate unsteady movement headache personality changesIf not treated, the patient may progress to severe
  • Hypoglycemia that can include: disorientation seizures unconsciousness deathThe occurrence of early symptoms calls for prompt
  • And, if necessary, repeated administration of some form of carbohydrate. Patients
  • Should always carry a quick source of sugar, such as candy mints or glucose
  • Tablets. The prompt treatment of mild hypoglycemic symptoms can prevent severe
  • Hypoglycemic reactions. If the patient does not improve or if administration
  • Of carbohydrate is impossible, glucagon should be given or the patient should
  • Be treated with intravenous glucose at a medical facility. Glucagon, a naturally
  • Occurring substance produced by the pancreas, is helpful because it enables
  • The patient to produce his/her own blood glucose to correct the hypoglycemia.POSSIBLE PROBLEMS WITH
  • GLUCAGON TREATMENTSide effects may include nausea and vomiting, a temporary increase in heart rate, and allergic reactions to glucagon or to one of the inactive ingredients in glucagon.If you experience any other reactions which are likely to have been caused by glucagon, please contact your doctor.STORAGEStore the kit at controlled room temperature between 20° to 25°C (68° to 77°F) before mixing glucagon with the diluent. Glucagon that has been mixed with diluent should be used immediately. Discard any unused portion. Solutions should be clear and of a water-like consistency at time of use.Literature revised April 2018Marketed by: Lilly USA, LLCIndianapolis, IN 46285, USACopyright © 1999, 2018, Eli Lilly and Company.
  • All rights reserved.GLU-0002-PPI-20180418

Package Label – Glucagon 1 Mg Emergency Kit 1Ct

LillyRx onlyGlucagon Emergency Kit for Low Blood SugarGlucagon for Injection 1 mg (1 unit)NDC 0002-8031-01MS8031Marketed by: Lilly USA, LLCIndianapolis, IN 46285, USAGlucagon: Product of AustriaDiluting Syringe: Product of Germany

* Please review the disclaimer below.